LuciEncor — Encorafenib 75 mg, 90 pcs, Lucius

LuciEncor — Encorafenib Capsules 75 mg, 90 Capsules

Product code: 518

75990₴ 82829₴ -8% On order · from 10 days

Analogues

Encoraf LuciEncor
1
Active ingredient
Dosage form Capsules
Capsules per pack 90

LuciEncor is a highly selective targeted antineoplastic agent belonging to the protein kinase inhibitor class, indicated for the treatment of unresectable or metastatic melanoma and colorectal cancer harboring BRAF V600 mutations. The active pharmaceutical ingredient is encorafenib at a strength of 75 mg supplied as hard gelatin capsules (Encorafenib Capsules 75 mg). The product is developed and manufactured by Lucius Pharmaceuticals.

Encorafenib is an oral selective BRAF kinase inhibitor (including mutant BRAF V600E, V600K, and V600D forms). The MAPK/ERK signaling pathway, in which BRAF plays a critical role, is frequently hyperactivated in various malignancies, driving uncontrolled cell division. Encorafenib blocks this pathway, suppressing tumor cell proliferation. The drug is typically administered in combination with MEK inhibitors (such as binimetinib) to overcome resistance and enhance therapeutic efficacy.

Supplied in a package containing 90 capsules of 75 mg. Intended exclusively for oral administration under the strict supervision of an oncologist.

Key Clinical Features and Advantages of LuciEncor 75 mg:

  • ✅ Selective BRAF V600 Inhibition: High selectivity for mutant BRAF forms to block oncogenic signaling.
  • ✅ Prolonged Kinase Suppression: Unique molecular structure ensures tight target binding and sustained half-life.
  • ✅ Combination Therapy: Proven synergistic efficacy when combined with MEK inhibitors in melanoma and colorectal cancer.
  • ✅ Convenient Strength: 75 mg capsules allow precise titration of the required daily dose.
  • ✅ Lucius Pharmaceuticals Standards: High-quality, accessible generic alternative to the originator product (Braftovi).

LuciEncor is supplied as hard gelatin capsules for oral administration.

Qualitative and Quantitative Composition per Capsule:

  • Active Ingredient: Encorafenib — 75 mg.
  • Excipients: Copovidone, colloidal anhydrous silica, microcrystalline cellulose, crospovidone, magnesium stearate. Capsule shell: gelatin, titanium dioxide, iron oxide red, iron oxide yellow, iron oxide black.

Packaging and Presentation: Hard capsules, 75 mg strength. Each package contains 90 capsules along with prescribing information. Labeled with LuciEncor (Encorafenib Capsules 75 mg) and Lucius Pharmaceuticals corporate graphics.

Pharmacodynamics:
Encorafenib is a potent oral reversible BRAF kinase inhibitor. BRAF gene mutations (such as V600E) result in constitutive activation of the MAPK/ERK signaling pathway, bypassing normal cell growth control. Encorafenib suppresses mutant BRAF kinase activity, arresting tumor cell proliferation. In combination with MEK inhibitors, it prevents or delays the onset of acquired resistance.

Pharmacokinetics:

  • Absorption: Following oral administration, encorafenib is rapidly absorbed; peak plasma concentration (Tmax) is achieved within approximately 1.5 to 2 hours. Food intake has no clinically significant effect on bioavailability.
  • Distribution: Human plasma protein binding is approximately 86%.
  • Metabolism: Extensively metabolized in the liver, primarily via cytochrome P450 enzymes (mainly CYP3A4, as well as CYP2C19 and CYP2D6).
  • Elimination: Excreted predominantly via feces (approx. 47% as metabolites) and renally (approx. 47%). Terminal elimination half-life (T1/2) averages approximately 3.5 hours.

LuciEncor is indicated in adult patients for (in the presence of confirmed BRAF V600 mutations):

  • Unresectable or Metastatic Melanoma: In combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
  • Metastatic Colorectal Cancer: In combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation who have received prior systemic therapy.

LuciEncor is administered orally once daily every day at approximately the same time.

Dosing Regimen:
The recommended standard dose for melanoma (in combination with binimetinib) is 450 mg (six 75 mg capsules) once daily. The recommended dose for colorectal cancer (in combination with cetuximab) is 300 mg (four 75 mg capsules) once daily.

Administration Guidelines:
Capsules should be swallowed whole with water; do not break, crush, or open. Can be taken with or without food. If vomiting occurs after capsule ingestion, do not take an extra dose — take the next dose as scheduled at the normal time.

Administration of LuciEncor is contraindicated in:

  • Hypersensitivity: Known hypersensitivity to encorafenib or any excipient.
  • Pregnancy and Lactation: Strictly contraindicated in pregnant or breastfeeding women.
  • Pediatric Population: Safety and efficacy in patients under 18 years have not been established.
  • Severe Hepatic or Renal Impairment: Pronounced liver or kidney dysfunction (requiring caution or dosage adjustment).

Encorafenib is metabolized primarily via CYP3A4 and acts as an inducer and inhibitor of certain transporters:

  • Strong and Moderate CYP3A4 Inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, grapefruit juice): Significantly elevate encorafenib plasma concentrations and toxicity risks (avoid concurrent use or reduce dose).
  • Strong and Moderate CYP3A4 Inducers (rifampicin, carbamazepine, phenytoin, St. John's Wort): Significantly decrease encorafenib blood concentrations and reduce efficacy (avoid concurrent use).
  • CYP3A4 Substrates: Encorafenib may induce or inhibit the metabolism of co-administered medicinal products.

Pregnancy:
LuciEncor is contraindicated during pregnancy. Based on its mechanism of action, encorafenib may cause fetal harm and embryotoxicity. Females of reproductive potential must utilize effective reliable contraception during treatment and for at least 1 month following the final dose.

Lactation:
Excretion of encorafenib into human breast milk is unstudied. Breastfeeding must be discontinued during treatment and for 2 weeks post-therapy.

The most frequent and clinically significant adverse reactions include (in combination regimens):

  • General Disorders: Fatigue, nausea, vomiting, diarrhea, constipation, abdominal pain.
  • Dermatologic Reactions: Hyperkeratosis, rash, alopecia, dry skin, palmar-plantar erythrodysesthesia.
  • Musculoskeletal System: Arthralgia, myalgia, pain in extremities.
  • Cardiovascular System: QT interval prolongation on ECG, left ventricular ejection fraction decrease (when combined with MEK inhibitors).
  • Laboratory Abnormalities: Elevations in liver transaminases (ALT, AST), increased blood creatine phosphokinase (CPK).

Symptoms:
Specific acute overdose symptoms of encorafenib are unestablished. Anticipated manifestations include exacerbated adverse reactions (gastrointestinal, dermatologic, and arthralgia).

Treatment:
No specific antidote exists. In case of overdose, withhold treatment and initiate supportive and symptomatic care under medical observation.

Storage Requirements for LuciEncor 75 mg:

  • 🌡️ Temperature Range: Store in original packaging in a dry place protected from light at temperatures below 30 °C.
  • 👶 Safety Precautions: Keep strictly out of reach of children (cytotoxic antineoplastic agent).
  • ⏳ Shelf Life: Stated on carton and blister pack. Don't use past expiration date. Prescription-only oncology medicine.

To verify authenticity of genuine LuciEncor 75 mg manufactured by Lucius Pharmaceuticals, inspect the following security and visual features:

  • ✅ Security Hologram & Scratch Code: Outer carton features an official Lucius Pharmaceuticals anti-counterfeit holographic seal with a scratch-off verification code for online validation via the manufacturer's official portal.
  • ✅ Corporate Branding: High-resolution printing displaying Lucius Pharmaceuticals graphics, Encorafenib Capsules 75 mg, and 90 Capsules count.
  • ✅ Factory Markings: Clearly printed Batch No., Mfg. Date, and Exp. Date matching across outer packaging and internal blister packs.
  • ✅ Prescribing Information: Includes an official product leaflet inside the outer carton.
On order · from 10 days
100% original product
Delivery across Ukraine
1

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 17.11.2026

Customer reviews

No reviews yet

Your review can be the first!

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00